A 26 week, double blinded, randomized, placebo controlled phase IIa clinical study to investigate the safety, pharmacokinetics and efficacy of oral administration of two doses of odiparcil in patients 16 years and above with MPS type VI receiving enzyme replacement therapy (ERT).

Trial Profile

A 26 week, double blinded, randomized, placebo controlled phase IIa clinical study to investigate the safety, pharmacokinetics and efficacy of oral administration of two doses of odiparcil in patients 16 years and above with MPS type VI receiving enzyme replacement therapy (ERT).

Planning
Phase of Trial: Phase II

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs Odiparcil (Primary)
  • Indications Mucopolysaccharidosis VI
  • Focus Adverse reactions
  • Acronyms iMProveS trial
  • Most Recent Events

    • 08 Sep 2017 New trial record
    • 29 Aug 2017 According to an Inventiva media release, this trial is expected to begin recruitment by year-end 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top